Associate Professor Peter White

Grants through ACH^2 ***have funded a high throughput screening (HTS) campaign against the Hepatitis C Virus (HCV) RNA polymerase***. The HCV RNA dependent RNA polymerase (RdRp) plays a key role in HCV replication and humans harbor non analogue; it is therefore an ideal drug target. There is an extremely active hunt for new polymerase inhibitors as none have yet reached phase III clinical trials. Our HTS has revealed four compounds with potent anti-viral activity, further work continues as we currently test derivatives of these primary hits a potential antivirals for HCV.